



Take an unfair advantage – Bionet compounds combine quality, activity and novelty from a single, reliable source.



**6L-585S**



**7L-365S**

Once again, the Bionet screening compound collection has been cited [1,2] as providing unique compounds with high biological activity. You will not find the majority of our screening compounds anywhere else. The reported [1] quinazolinones 6L-585S (mdivi-1 [3]) and 7L-365S are unique to Bionet and have the ability to selectively inhibit mitochondrial division, a function that plays an important role in the regulation of apoptosis. A. Cassidy-Stone *et al.* [1] screened approximately 23,000 compounds, representative of several commercially available libraries, and identified our compounds as a potential class of therapeutics for stroke, myocardial infarction, and neurodegenerative diseases. A. Tanaka and R.J. Youle also suggested that chemical inhibitors, such as mdivi-1 (Bionet 6L-585S), should prompt further explorations of the many remaining mysteries of mitochondrial division [2].

Sample the high quality of Bionet compounds for yourself. Bionet Diverse Subsets are available as 2,000, 5,000, and 10,000 compound libraries and they are supplied as 1mg samples pre-plated (therefore usually available for immediate dispatch) in 96 well Matrix plates (with rows 1 and 12 empty). These diversity sets offer a representative and cost-effective 'taster' of the entire catalogue, to enable targeted follow-up purchase of specific Bionet compounds most closely matching the clients' particular areas of interest.

1. A. Cassidy-Stone *et al.*, (2008). *Developmental Cell*, 14, 193-204.
2. A. Tanaka & R.J. Youle, (2008). *Molecular Cell*, 29, 409-410.
3. mdivi-1, mitochondrial division inhibitor-1.